Vet Med - Czech, 2017, 62(2):74-80 | DOI: 10.17221/100/2016-VETMED

Pax5 as a potential candidate marker for canine B-cell lymphomaOriginal Paper

S. Sirivisoot1, S. Techangamsuwan1, S. Tangkawattana2, A. Rungsipipat*,1
1 Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand
2 Faculty of Veterinary Medicine, Khon Kaen University, Khon Kaen, Thailand

Immunophenotyping is a valuable method for prognosis in canine malignant lymphoma. The general B-cell marker is CD79a; however, Pax5 or B-cell specific activator protein, a transcription factor that controls B-cell identity and cell maturation, could also be used as a B-cell indicator in canine lymphomas. This study aimed to use Pax5, CD79a and CD3 expression in immunohistochemistry of spontaneous canine lymphomas, in order to carry out diagnosis and histopathological classification according to the World Health Organization guidelines. Forty-six retrospective cases including 33 multicentric, eight extranodal, and five alimentary lymphomas in dogs were immunostained by anti-Pax5 and anti-CD79a antibodies for B-cell identification, and anti-CD3 antibody for T-cell identification. T-cell lymphomas (CD3+/Pax5-/CD79a-) accounted for 30.43% of cases (14/46), and four of the lymphomas (28.57%) presented with CD3+/Pax5-/CD79a+. Conversely, B-cell lymphomas (CD3-/Pax5+/CD79a+) accounted for 69.57% of cases (32/46) and 12.5% of these (4/32) showed only Pax5-positive cells (CD3-/Pax5+/CD79a-). Therefore, in dogs, Pax5 appears to be a more useful marker for staining all B-cell subtypes compared to CD79a. Immunophenotyping with both Pax5 and CD3 are necessary for lymphoid lineage identification in canine lymphomas.

Keywords: B-cell marker; dog; immunohistochemistry; lymphoma

Published: February 28, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sirivisoot S, Techangamsuwan S, Tangkawattana S, Rungsipipat A. Pax5 as a potential candidate marker for canine B-cell lymphoma. Vet Med - Czech. 2017;62(2):74-80. doi: 10.17221/100/2016-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Agostinelli C, Sabattini E, Gjorret JO, Righi S, Rossi M, Mancini M, Piccaluga PP, Bacci F, Marafioti T, Bettini G, Falini B, Pileri SA (2010): Characterization of a new monoclonal antibody against pax5/basp in 1525 paraffinembedded human and animal tissue samples. Applied Immunohistochemistry and Molecular Morphology 18, 561-572. Go to original source... Go to PubMed...
    2. Browne P, Petrosyan K, Hernandez A, Chan JA (2003): The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. American Journal of Clinical Pathology 120, 767-777. Go to original source...
    3. de Arespacochaga AG, Schwendenwein I, Weissenbock H (2007): Retrospective study of 82 cases of canine lymphoma in Austria based on the working formulation and immunophenotyping. Journal of Comparative Pathology 136, 186-192. Go to original source... Go to PubMed...
    4. Desouki MM, Post GR, Cherry D, Lazarchick J (2010): Pax5: A valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms. Clinical Medicine and Research 8, 84-88. Go to original source... Go to PubMed...
    5. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL (2002): Canine neoplasia in the UK: Estimates of incidence rates from a population of insured dogs. Journal of Small Animal Practice 43, 240-246. Go to original source... Go to PubMed...
    6. Dvir E, Schoeman JP, Clift SJ, Mcneilly TN, Mellanby RJ (2011): Immunohistochemical characterization of lymphocyte and myeloid cell infiltrates in spirocercosis-induced oesophageal nodules. Parasite Immunology 33, 545-553. Go to original source... Go to PubMed...
    7. Fernandes NC, Guerra JM, Ressio RA, Wasques DG, Etlinger-Colonelli D, Lorente S, Nogueira E, Dagli ML (2015): Liquid-based cytology and cell block immunocytochemistry in veterinary medicine: Comparison with standard cytology for the evaluation of canine lymphoid samples. Veterinary and Comparative Oncology, DOI: 10.1111/vco.12137. Go to original source... Go to PubMed...
    8. Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A (2005): Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. Journal of Clinical Oncology 23, 6364-6369. Go to original source... Go to PubMed...
    9. Ferrer L, Fondevila D, Rabanal R, Tarres J, Ramis A (1993): Immunohistochemical detection of CD3 antigen (pan T marker) in canine lymphomas. Journal of Veterinary Diagnostic Investigation 5, 616-620. Go to original source... Go to PubMed...
    10. Fournel-Fleury C, Magnol JP, Bricaire P, Marchal T, Chabanne L, Delverdier A, Bryon PA, Felman P (1997): Cytohistological and immunological classification of canine malignant lymphomas: Comparison with human nonHodgkin's lymphomas. Journal of Comparative Pathology 117, 35-59. Go to original source... Go to PubMed...
    11. Fournel-Fleury C, Ponce F, Felman P, Blavier A, Bonnefont C, Chabanne L, Marchal T, Cadore JL, Goy-Thollot I, Ledieu D, Ghernati I, Magnol JP (2002): Canine T-cell lymphomas: A morphological, immunological, and clinical study of 46 new cases. Veterinary Pathology 39, 92-10. Go to original source... Go to PubMed...
    12. Horcher M, Souabni A, Busslinger M (2001): Pax5/bsap maintains the identity of B cells in late B lymphopoiesis. Immunity 14, 779-790. Go to original source... Go to PubMed...
    13. Jensen KC, Higgins JP, Montgomery K, Kaygusuz G, Van De Rijn M, Natkunam Y (2007): The utility of pax5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms. Modern Pathology 20, 871-877. Go to original source... Go to PubMed...
    14. Nasr MR, Rosenthal N, Syrbu S (2010): Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and Burkitt lymphoma: Usefulness of pax5 immunostaining as pan-pre-B-cell marker. American Journal of Clinical Pathology 133, 41-48. Go to original source... Go to PubMed...
    15. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Fournel-Fleury C (2004): Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy. Veterinary Journal 167, 158-166. Go to original source... Go to PubMed...
    16. Rebhun RB, Kent MS, Borrofka SA, Frazier S, Skorupski K, Rodriguez CO (2011): CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma. Veterinary and Comparative Oncology 9, 38-44. Go to original source... Go to PubMed...
    17. Regan RC, Kaplan MS, Bailey DB (2013): Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: Results of a survey of veterinarians. Veterinary and Comparative Oncology 11, 287-295. Go to original source... Go to PubMed...
    18. Rungsipipat A, Chayapong J, Jongchalermchai J, Thongruk T, Manachai N, Wangnaitham S, Techangamsuwan S (2012): Histopathological classification and immunophenotyping of spontaneous canine lymphoma in Bangkok metropolitan. Comparative Clinical Pathology 23, 213- 222. Go to original source...
    19. Schaffer PA, Charles JB, Tzipory L, Ficociello JE, Marvel SJ, Barrera J, Spraker TR, Ehrhart EJ (2012): Neurolymphomatosis in a dog with B-cell lymphoma. Veterinary Pathology 49, 771-774. Go to original source... Go to PubMed...
    20. Sirivisoot S, Techangamsuwan S, Tangkawattana S, Rungsipipat A (2016): Application of immunophenotyping and heteroduplex polymerase chain reaction (hPARR) for diagnosis of canine lymphomas. Asian Pacific Journal of Cancer Prevention 17, 2909-2916.
    21. Stone BM, Gan D (2014): Application of the tissue transfer technique in veterinary cytopathology. Veterinary Clinical Pathology 43, 295-302. Go to original source... Go to PubMed...
    22. Valli VE, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F, Durham A, Ehrhart EJ, Johnson Y, Jones C, Kiupel M, Labelle P, Lester S, Miller M, Moore P, Moroff S, Roccabianca P, Ramos-Vara J, Ross A, Scase T, Tvedten H, Vernau W (2011): Classification of canine malignant lymphomas according to the World Health Organization criteria. Veterinary Pathology 48, 198-211. Go to original source... Go to PubMed...
    23. Valli VE, Kass PH, San Myint M, Scott F (2013): Canine lymphomas: Association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. Veterinary Pathology 50, 738-748. Go to original source... Go to PubMed...
    24. Vezzali E, Parodi AL, Marcato PS, Bettini G (2010): Histopathologic classification of 171 cases of canine and feline non-hodgkin lymphoma according to the WHO. Veterinary and Comparative Oncology 8, 38-49. Go to original source... Go to PubMed...
    25. Weiss DJ (2006): A retrospective study of the incidence and the classification of bone marrow disorders in the dog at a veterinary teaching hospital (1996-2004). Journal of Veterinary Internal Medicine 20, 955-961. Go to original source...
    26. Wilkerson MJ, Dolce K, Koopman T, Shuman W, Chun R, Garrett L, Barber L, Avery A (2005): Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules. Veterinary Immunology and Immunopathology 106, 179-196. Go to original source... Go to PubMed...
    27. Willmann M, Mullauer L, de Arespacochaga AG, Reifinger M, Mosberger I, Thalhammer JG (2009): Pax5 immunostaining in paraffin-embedded sections of canine nonHodgkin lymphoma: A novel canine pan pre-B- and B-cell marker. Veterinary Immunology and Immunopathology 128, 359-365. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content